scholarly journals Satisfaction With Medical Care in Patients With Atrial Fibrillation Treated With Vitamin K Antagonists Versus New Oral Anticoagulants

2015 ◽  
Vol 68 (6) ◽  
pp. 537-539 ◽  
Author(s):  
Manuel Anguita ◽  
Francisco Marín ◽  
Inmaculada Roldán ◽  
Angel Cequier ◽  
Vicente Bertomeu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Medical Care ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants

scholarly journals New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation

2014 ◽  
Vol 11 (7) ◽  
pp. 680-684 ◽  
Author(s):  
Josep M. Alegret ◽  
Xavier Viñolas ◽  
Miguel A. Arias ◽  
Antoni Martínez-Rubio ◽  
Pablo Rebollo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atrial Fibrillation ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

One decade of oral anticoagulation in stroke patients: Results from a large country-wide hospital-based registry

2017 ◽  
Vol 13 (3) ◽  
pp. 308-312 ◽  
Author(s):  
Christian Tanislav ◽  
Jens Allendörfer ◽  
Waltraud Pfeilschifter ◽  
Sven Fuest ◽  
Marco Stein ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Oral Anticoagulants ◽  
Federal State ◽  
Stroke Patients ◽  
Large Country ◽  
Previous Medication ◽  
Ischemic Attack

Background New evidence regarding stroke prevention in atrial fibrillation has been published. Implementing knowledge into clinical practice remains challenging. Aims To investigate oral anticoagulants in stroke patients documented in a nationwide registry. Methods The database is an obligatory federal-state-wide hospital-based registry that covers more than 95% of all ischemic strokes, transient ischemic attacks and intracerebral hemorrhages in a community of more than six million inhabitants (Hesse/Germany). We analyzed oral anticoagulants prescribed on discharge in patients with stroke or transient ischemic attack during 2006–2015. Results From 2006 to 2015, we annually selected median 20,895 patients. From 2006 to 2015, the proportion of patients treated with oral anticoagulants increased (9.8% to 24%). The annual proportion of patients with atrial fibrillation remained constant (median: 23%). In atrial fibrillation patients treated with oral anticoagulants, the age increased (median 2008/2009: 76.9 years vs. 2014/2015 79.4 years). The percentage of treated individuals in atrial fibrillation increased dramatically (2006: 30.1% to 2015: 74.5%); in 2015, 30.8% of these patients received vitamin K antagonists and 70.2% new oral anticoagulants. Independent factors associated with new oral anticoagulants therapy were a previous medication with new oral anticoagulants and a treatment on stroke unit. Between new oral anticoagulants- and vitamin K antagonists-treated patients (2015), no differences in age were noted (both mean: 79.4 years). Conclusions The new oral anticoagulants availability enhanced a general trend treating more target patients with oral anticoagulants.

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.

2011 ◽  
Vol 106 (11) ◽  
pp. 868-876 ◽  
Author(s):  
Luciano Crippa ◽  
Anna Falanga ◽  
Guido Finazzi ◽  
Francesco Marongiu ◽  
Gualtiero Palareti ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Vitamin K ◽  
Stroke Prevention ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
New Drugs ◽  
New Oral Anticoagulants ◽  
Laboratory Control ◽  
Questions And Answers

SummaryDabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

Sign in / Sign up

Export Citation Format

Share Document